Trial Results Support At-Home Treatment of Edema in Heart Failure with Subcutaneous Furosemide as an Effective and Safe Alternative to Inpatient Hospital Care
“SUBCUT HF II, a randomized controlled investigator-sponsored trial of at-home subcutaneous furosemide for heart failure–related edema, meets its primary and key secondary endpoints, supporting the safety and efficacy of patient self-treatment outside the hospital.”
Our CEO Nick Hartshorne-Evans through Pumping Marvellous has had involvement in this project from the beginning.
“BURLINGTON, Mass., May 11, 2026 /PRNewswire/ — SQ Innovation today announced topline results from the SUBCUT HF II trial of its product Lasix® ONYU, a novel subcutaneous formulation of furosemide for people with heart failure-associated edema. Patients randomized to treatment at home spent an average of four (4) fewer days in the hospital compared to those treated with standard-of-care intravenous (IV) furosemide, according to the trial’s results, presented May 9 at Heart Failure 2026, the annual congress of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), in Barcelona, Spain.
SUBCUT HF II is a multicenter, open-label, randomized controlled trial conducted across 20 National Health Service (NHS) hospitals in the U.K. The trial was co-sponsored by the University of Glasgow and the National Health Service (U.K.) Greater Glasgow and Clyde Health Board and led by Principal Investigators Dr. Ross T. Campbell and Professor Mark C. Petrie of the Glasgow Cardiovascular Research Centre, University of Glasgow.”